{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Efficacy and Safety of Cemdisiran siRNA in Myasthenia Gravis","description":"Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis. &amp;nbsp;Show citation:&amp;nbsp; Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.&amp;nbsp;Lancet. 2026;407(10540):1712-1725. doi:10.1016\/S0140-6736(26)00690-2&amp;nbsp; ","author_name":"Neurology Minute","author_url":"https:\/\/www.aan.com\/education-and-research\/online-learning-programs\/podcasts\/neurology-minute-podcast","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42414240\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/45403e\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/42414240"}